Z. Lange

Abstract PS17-11: Her2-xpat, a novel protease-activatable prodrug t-cell engager (tce), exhibits potent t-cell activation and efficacy in her2 tumors, yielding large predicted safety margins based on non-human primate (nhp)

F. Cattaruzza, T. Dao-Pick, V. Schellenberger, 2021 .

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

K. Morrissey, F. Cattaruzza, Milton To, 2023, Nature Cancer.